Multimodal treatment in operable breast cancer: Five-year results of the CMF programme

A. Rossi, G. Bonadonna, P. Valagussa, U. Veronesi

Research output: Contribution to journalArticle

Abstract

The five-year results of a prospective randomised trial of radical mastectomy (179 patients) versus radical mastectomy followed by adjuvant chemotherapy (207 patients) were analysed. Chemotherapy consisted of 12 monthly cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF). Both relapse-free survival (controls 44.6%, CMF group 59.5%) and total survival (controls 66.2%, CMF group 78.4%) were significantly improved. The findings were related to the number of diseased axillary nodes and amount of drug administered, and were independent of CMF-induced amenorrhoea. Menopausal state alone appeared to affect the five-year results only when the amount of drug administered was not taken into account. Salvage treatment at first relapse failed to improve total survival in the controls compared with the CMF group. Acute toxic manifestations were moderate and reversible. Chronic organ damage and increased incidence of second neoplasms (controls 1.7%, CMF group 1.4%) were not observed. The multimodality approach to treatment of primary breast cancer is a new and important advance. This and other studies are continuing.

Original languageEnglish
Pages (from-to)1427-1431
Number of pages5
JournalBritish Medical Journal
Volume282
Issue number6274
Publication statusPublished - 1981

Fingerprint

Combined Modality Therapy
Methotrexate
Fluorouracil
Cyclophosphamide
Breast Neoplasms
Radical Mastectomy
Survival
Recurrence
Salvage Therapy
Second Primary Neoplasms
Poisons
Amenorrhea
Adjuvant Chemotherapy
Pharmaceutical Preparations
Drug Therapy
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rossi, A., Bonadonna, G., Valagussa, P., & Veronesi, U. (1981). Multimodal treatment in operable breast cancer: Five-year results of the CMF programme. British Medical Journal, 282(6274), 1427-1431.

Multimodal treatment in operable breast cancer : Five-year results of the CMF programme. / Rossi, A.; Bonadonna, G.; Valagussa, P.; Veronesi, U.

In: British Medical Journal, Vol. 282, No. 6274, 1981, p. 1427-1431.

Research output: Contribution to journalArticle

Rossi, A, Bonadonna, G, Valagussa, P & Veronesi, U 1981, 'Multimodal treatment in operable breast cancer: Five-year results of the CMF programme', British Medical Journal, vol. 282, no. 6274, pp. 1427-1431.
Rossi A, Bonadonna G, Valagussa P, Veronesi U. Multimodal treatment in operable breast cancer: Five-year results of the CMF programme. British Medical Journal. 1981;282(6274):1427-1431.
Rossi, A. ; Bonadonna, G. ; Valagussa, P. ; Veronesi, U. / Multimodal treatment in operable breast cancer : Five-year results of the CMF programme. In: British Medical Journal. 1981 ; Vol. 282, No. 6274. pp. 1427-1431.
@article{81839941dc954629b765f0bf8f5c41c0,
title = "Multimodal treatment in operable breast cancer: Five-year results of the CMF programme",
abstract = "The five-year results of a prospective randomised trial of radical mastectomy (179 patients) versus radical mastectomy followed by adjuvant chemotherapy (207 patients) were analysed. Chemotherapy consisted of 12 monthly cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF). Both relapse-free survival (controls 44.6{\%}, CMF group 59.5{\%}) and total survival (controls 66.2{\%}, CMF group 78.4{\%}) were significantly improved. The findings were related to the number of diseased axillary nodes and amount of drug administered, and were independent of CMF-induced amenorrhoea. Menopausal state alone appeared to affect the five-year results only when the amount of drug administered was not taken into account. Salvage treatment at first relapse failed to improve total survival in the controls compared with the CMF group. Acute toxic manifestations were moderate and reversible. Chronic organ damage and increased incidence of second neoplasms (controls 1.7{\%}, CMF group 1.4{\%}) were not observed. The multimodality approach to treatment of primary breast cancer is a new and important advance. This and other studies are continuing.",
author = "A. Rossi and G. Bonadonna and P. Valagussa and U. Veronesi",
year = "1981",
language = "English",
volume = "282",
pages = "1427--1431",
journal = "British Medical Journal",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "6274",

}

TY - JOUR

T1 - Multimodal treatment in operable breast cancer

T2 - Five-year results of the CMF programme

AU - Rossi, A.

AU - Bonadonna, G.

AU - Valagussa, P.

AU - Veronesi, U.

PY - 1981

Y1 - 1981

N2 - The five-year results of a prospective randomised trial of radical mastectomy (179 patients) versus radical mastectomy followed by adjuvant chemotherapy (207 patients) were analysed. Chemotherapy consisted of 12 monthly cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF). Both relapse-free survival (controls 44.6%, CMF group 59.5%) and total survival (controls 66.2%, CMF group 78.4%) were significantly improved. The findings were related to the number of diseased axillary nodes and amount of drug administered, and were independent of CMF-induced amenorrhoea. Menopausal state alone appeared to affect the five-year results only when the amount of drug administered was not taken into account. Salvage treatment at first relapse failed to improve total survival in the controls compared with the CMF group. Acute toxic manifestations were moderate and reversible. Chronic organ damage and increased incidence of second neoplasms (controls 1.7%, CMF group 1.4%) were not observed. The multimodality approach to treatment of primary breast cancer is a new and important advance. This and other studies are continuing.

AB - The five-year results of a prospective randomised trial of radical mastectomy (179 patients) versus radical mastectomy followed by adjuvant chemotherapy (207 patients) were analysed. Chemotherapy consisted of 12 monthly cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF). Both relapse-free survival (controls 44.6%, CMF group 59.5%) and total survival (controls 66.2%, CMF group 78.4%) were significantly improved. The findings were related to the number of diseased axillary nodes and amount of drug administered, and were independent of CMF-induced amenorrhoea. Menopausal state alone appeared to affect the five-year results only when the amount of drug administered was not taken into account. Salvage treatment at first relapse failed to improve total survival in the controls compared with the CMF group. Acute toxic manifestations were moderate and reversible. Chronic organ damage and increased incidence of second neoplasms (controls 1.7%, CMF group 1.4%) were not observed. The multimodality approach to treatment of primary breast cancer is a new and important advance. This and other studies are continuing.

UR - http://www.scopus.com/inward/record.url?scp=0019472220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019472220&partnerID=8YFLogxK

M3 - Article

C2 - 6784849

AN - SCOPUS:0019472220

VL - 282

SP - 1427

EP - 1431

JO - British Medical Journal

JF - British Medical Journal

SN - 0959-8146

IS - 6274

ER -